Objective: To investigate the utility of HPV DNA testing and p16/Ki-67 dual staining for detecting CIN2+ and CIN3 in women referred to colposcopy with minor abnormal cervical cytology LSIL and AS-CUS. The clinical performance of both tests was evaluated as standalone tests and combined tests, for detection CIN2+ and CIN3 over 2 years.
Introduction
Based on the known causal relationship between high risk human papillomavirus (HR HPV) and cervical cancer (1) , HPV testing has become an important tool in developing strategies for cervical cancer screening. It was initially approved as a triage test for minor cytological abnormalities, providing improved detection of cervical intraepithelial grade 2 or worse (CIN2+) compared with repeat cytology (2) (3) (4) . However, despite the utility of HPV testing in triage, concern remains over the reported suboptimal specificity of HPV DNA based tests (5) . This is due to the fact that HPV DNA testing cannot discriminate transforming infections from transient infections of minor clinical relevance. Knowledge of HPV pathophysiology has enabled the identification of a number of biomarkers with potential to distinguish those at risk of disease progression. Several host cell biomarkers have been evaluated for their potential to improve the diagnostic specificity of cervical screening (6) . One of the most promising cellular protein markers to be identified is the cyclin dependent kinase inhibitor p16 INK4A (referred to as p16 hereafter) (7) (8) (9) . However, p16 can be over expressed in some non-dyskaryotic cells (10) and, as a consequence, morphological criteria are needed (11) . It is known that increased expression of p16 signals functional activation of E2F mediated by HPV E7. Combining p16 with the proliferation marker Ki-67 signals HPV transformed cells undergoing proliferation. Studies have reported on the clinical performance of dual staining for p16 and Ki-67 for detection of CIN2+ and CIN3 (13) (14) (15) (16) (17) (18) (19) .
However, longitudinal data is limited on its utility as a triage tool for minor cytological abnormalities LSIL (low grade squamous intraepithelial lesion) and ASC-US (atypical cells of undetermined significance).
The purpose of this two year prospective study was to examine two testing modalities, HPV DNA and p16-Ki-67, with an aim to identify an approach to best manage women with LSIL and ASCUS on cytology.
Materials and Methods

Study population
The study setting was Ireland. 68 was performed using Hybrid Capture 2 (HC2) (Qiagen, GmbH, Hilden, Germany), as described by the manufacturer. The RLU/CO negative cut off value was 1.0. Specimens below this detection limit were considered negative.
p16/Ki-67 dual stain
Cytology slides from residual ThinPrep® material, from the same sample used for HPV testing, were prepared using a T2000 slide processor. The CINtec PLUS® kit (Roche mtm Laboratories AG, Mannheim, Germany) was used for ICC staining of p16 and Ki-67 in accordance with the manufacturer's instructions. A positive result was interpreted as brown cytoplasmic staining for p16 expression and red nuclear staining for Ki-67 expression. The presence of one or more stained epithelial cells,
showing simultaneous expression, signified a positive result. All cases were subjected to a pathologist review, blinded to histology and HPV status. All testing on ThinPrep® Specimens was performed within three months of obtaining the specimen. Results from HPV testing and ICC were not disclosed to the participants or used for patient management.
Statistical Analysis
The final outcome was based on the histological grade taken as the worse of the histological findings on punch biopsy or LLETZ during a patient's time at colposcopy. The primary disease endpoint was histologically confirmed CIN2+ and CIN3, diagnosed within two years of the first colposcopy visit. While staining for p16 has been recommended to improve diagnosis of CIN2 (20) Figure 1A ). Figure 1B From the overall population 62.2% were positive for HPV DNA, 41.6% of whom had CIN2+ and 15.6% had CIN3 over the study period. There were 30.4% with a positive p16/Ki-67 result, 72.0% had a CIN2+ and 27.3% had a CIN3 diagnosis.
Clinical outcome following combined testing of p16/Ki-67 and HPV DNA, is shown in figure 2 . From the general population of 471 women, 29.5% had a double positive test result; 74.1% of these women had CIN2+ and 27.3% had CIN3
diagnosed. Over two years, the absolute risk of CIN2+ and CIN3 was 15% and 6.3% in women with a positive HPV result and a negative p16/Ki-67 result. The absolute risk of CIN2+ was 5.4% and CIN3 was 1.2% in women with a negative HPV DNA and negative p16/Ki-67 result.
Discussion
Minor abnormalities, LSIL and ASC-US, represent a large burden at colposcopy. A large proportion of these will not lead to a diagnosis of CIN2+ or CIN3 yet still remain under extensive follow up. Efforts have been made to manage this by introducing HPV DNA triage of minor abnormal cytology. However, due to the low specificity, HPV DNA testing can still lead to over-referral to colposcopy. In this study we investigated potential options for triaging women attending colposcopy following repeat minor abnormal cytology. We found from a population of women attending colposcopy with LSIL and ASCUS on cytology only 29.3% and 10.2%
had underlying or subsequent CIN2+ and CIN3 lesions over two years. We have shown that a combined HPV DNA and p16/Ki-67 testing approach could be a potential tool for predicting diagnosis of CIN2+ and CIN3 in these women.
The two triage modalities, p16/Ki-67 and HPV DNA, were initially explored as standalone tests. HPV DNA was over three times higher than p16/Ki-67 in women with persistent low grade lesions and those discharged with no CIN. Unlike HPV DNA testing, there was no significant difference in the proportion of women with p16/Ki-67 co-expression between LSIL and ASC-US referred patients, an important finding considering the reported limited use of HPV DNA triage in LSIL (2, 3) . Furthermore p16/Ki-67 showed only a modest difference in performance with respect to age of women compared to HPV testing, which showed a substantially reduced specificity in women under the age of 30 years. On the other hand, compared to p16/Ki-67, HPV DNA was positive in a significantly higher proportion of CIN2+ and CIN3 (p<0.001). This highlights the lower sensitivity of p16/Ki-67 compared to HPV DNA testing. Although, sensitivity for p16/Ki-67 in the current study is similar to previous studies (13) (14) (15) (16) (17) (18) (19) . Generally PPV appeared low, this is due to the low prevalence of CIN3 in this population, 10%, and is in line with other studies showing a similar prevalence of CIN3 (14, 15, 18) . Overall specificity and PPV demonstrated by p16/Ki-67 remained higher than that demonstrated by HPV DNA across all categories. However as HPV DNA testing outperformed with respect to sensitivity and NPV we investigated a combined testing approach in order to maintain the high sensitivity of HPV testing and improve specificity with p16/Ki-67.
When combined, 29.5% were found to be positive for both tests, from these 74.1% had CIN2+ and 27.3% CIN3 diagnosed. Combined testing presented the most efficient option for identifying CIN2+ and CIN3 in women with repeat minor abnormal cytology as it identified almost one third of the population as requiring immediate colposcopy, signified by a double positive result. A negative p16/Ki-67
and negative HPV DNA maintained a high level of reassurance against CIN3
(1.2%) similar to that of a negative HPV test alone. A risk of CIN3 <2% has been previously deemed safe to allow return to routine recall (20) . An important consideration in the use of a combined testing approach is how to manage women with discordant results, i.e. who are HPV positive p16/Ki-67 negative. Due to the risk of CIN2+ and CIN3 in these individuals it would probably be best advised that they do not return to routine recall but have some form of follow-up or colposcopy
referral. An approach of repeat HPV testing of women who are HPV positive cytology negative after one year has been previously recommended (21) .
The strengths of this study are that enrolment was systematic through the Irish national screening program, CervicalCheck. Women were managed under a standard protocol outlined by CervicalCheck guidelines. These attributes allowed test performance to be evaluated in a routine population-based setting. The consequence of this real-world setting was, however, that some women were not managed according to the protocol, but this probably reflects the day-to-day reality of colposcopy clinics. A limitation of this study it that it focused on a population of women attending colposcopy on the bases of repeat minor cytology rather than a single ASC-US or LSIL, which a secondary test would be applied.
However, sensitivity in the current study remains consistent with previous studies (13) (14) (15) (16) (17) (18) (19) . While a large number of samples were excluded based on low cellularity this is likely due to the fact two or more tests were performed on the samples prior to the ThinPrep® slide been made. In reality a triage test would be performed following only one HPV test, as such we do not anticipate cellularity to be an issue.
While this work has established that HPV DNA and p16/Ki-67 may play a role in cervical screening programmes, large studies with long term follow up are warranted in order to determine an optimal management algorithm. Management of HPV DNA positive p16/Ki-67 negative women will need to be addressed in order to predict the intervals for retesting and return to routine screening. Moreover, further studies investigating triage following an initial minor cytological abnormality and in the context of primary screening with HPV will be important.
Currently triage of primary screened HPV positive women by cytology is recommended however a question still remains over how to manage HPV positive cytology negative women. Dual staining for p16/Ki-67 has been previously shown to help further stratify Pap negative/HPV positive women that at a highest risk of underlying high-grade disease (19) . In addition, cost-effective analysis will be an important aspect to help provide guidelines on the delivery and implementation in of such models in cervical screening. While other studies have found p16/Ki-67 superior to HPV E6/E7 mRNA testing by the APTIMA HPV assay (18) , further studies on the role of the ATPIMA assay in combination with p16/Ki-67, in addition to number of positive cells and morphology should be explored.
In conclusion, we have shown that combining HPV DNA positive women with p16/Ki-67 testing could lead to more accurate stratification of CIN in women presenting with minor cytology, potentially reducing referrals to colposcopy. This strategy is worthy of further evaluation in terms of both clinical-effectiveness and cost-effectiveness. While adding an additional test to screening may be more costly, introducing further stratification of minor abnormalities, prior to colposcopy rather than at colposcopy, should reduce unnecessary work up and treatment.
This will benefit women by reducing the psychosocial effects endured from having repeat abnormal smears and attending colposcopy clinics, in addition to reducing cost associated with colposcopy visits (22) .
